Outcome | Hazard ratio (95% CI) | P value |
---|---|---|
ANC recovery | ||
 Cohort ATG-PTCy vs ATG | 0.29 (0.21–0.41) | < 0.001 |
Other significant factors | ||
 Mononuclear cell count | 1.09 (1.04–1.14) | < 0.001 |
 CD34+ cell count | 1.08 (1.01–1.15) | 0.012 |
Platelet recovery | ||
 Cohort ATG-PTCy vs ATG | 0.30 (0.21–0.42) | < 0.001 |
Other significant factors | ||
 Mononuclear cell count | 1.06 (1.01–1.11) | 0.008 |
Acute GvHD ≥ grade 2 | ||
 Cohort ATG-PTCy vs ATG | 0.58 (0.35–0.96) | 0.036 |
Acute GvHD ≥ grade 3 | ||
 Cohort ATG-PTCy vs ATG | 0.28 (0.11–0.69) | 0.006 |
Total chronic GvHD | ||
 Cohort ATG-PTCy vs ATG | 0.60 (0.38–0.99) | 0.047 |
Non-relapse mortality | ||
 Cohort ATG-PTCy vs ATG | 0.26 (0.08–0.75) | 0.014 |
Disease risk index | ||
 Low/int vs high | 0.28 (0.12–0.68) | 0.005 |
Relapse | ||
 Cohort ATG-PTCy vs ATG | 0.65 (0.28–1.50) | 0.31 |
Disease-free survival | ||
 Cohort ATG-PTCy vs ATG | 0.44 (0.22–0.86) | 0.016 |
Disease risk index | ||
 Low/int vs high | 0.51 (0.27–0.99) | 0.048 |
Overall survival | ||
 Cohort ATG-PTCy vs ATG | 0.47 (0.22–1.01) | 0.055 |
Disease risk index | ||
 Low/int vs high | 0.48 (0.23–0.99) | 0.048 |
GVHD and relapse-free survival | ||
 Cohort ATG-PTCy vs ATG | 0.59 (0.38–0.92) | 0.021 |